Minneapolis, MNNCT02437396Now EnrollingIRB Ready

Gaucher Disease Type I Clinical Trial in Minneapolis, MN

Access cutting-edge gaucher disease type i treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by University of Minnesota

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access gaucher disease type i specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gaucher disease type i treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this gaucher disease type i clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Gaucher Disease Type I Study in Minneapolis

The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.

Sponsor: University of Minnesota

Who Can Participate

Inclusion Criteria

All participants must be 18 years or older.
All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.
Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.
GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).
GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.
All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.

Exclusion Criteria

Medically unstable conditions in any group as determined by the investigators
Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.
Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception
History of asthma that is presently being treated
Subjects who cannot or are unwilling to have blood drawn
Unable to adhere to study protocol for whatever reason

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT02437396) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gaucher Disease Type I Treatment Options in Minneapolis, MN

If you're searching for gaucher disease type i treatment options in Minneapolis, MN, this clinical trial (NCT02437396) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gaucher disease type i specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gaucher disease type i clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Minneapolis, MN

See all pulmonary embolism clinical trials recruiting in Minneapolis — not just this study.

Browse Pulmonary Embolism Trials in Minneapolis →

Browse More Trials by Condition

Pulmonary Embolism TrialsUlcerative Colitis TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsGaucher Disease TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN